Abstract
Cancer Immunology The ability of dendritic cells (DCs) to process and present antigens to the immune system makes them intriguing candidates for the development of cancer immunotherapies. Zhou et al. investigated whether the CD103+ tissue-resident conventional DC1 (cDC1) subset could control tumors in mouse models. DCs were grown and activated in cell culture using an immunostimulant called polyinosinic:polycytidylic acid (poly I:C). The cells were then loaded with tumor antigens and injected into mice to assess their vaccine potential. The authors found that in vitro–generated CD103+ cDC1s restrained melanoma and osteosarcoma tumor growth. Tumors could be further hindered if the in vitro–generated cDC1s were combined with immune checkpoint blockade treatment. J. Immunother. Cancer 8 , e000474 (2020).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call